Much Ado About Nothing Much With Atara's MS Hopeful
Interim Analysis On ATA188 Reveals Little
Investors and most analysts were not impressed with a much-anticipated Phase II update on Atara’s allogeneic T-cell immunotherapy which could be transformational as a treatment for multiple sclerosis, but some observers believe the slump in the firm’s stock was not merited.
